发布时间: 2025 - 11 - 24
Recently, Jingwei Shida Medical Technology Co., Ltd. ("Jingwei Shida") announced the completion of a new financing round exceeding RMB 100 million, co-led by Efung Zhuohua Fund, Huabin Fengtai Private Equity Fund, and Changfei Industrial Fund. The funds will be primarily used for continued R&D, scaled production, clinical application promotion, and global commercialization of confocal microscopy endoscopy products.As a high-end medical device enterprise focused on precision diagnosis and treatment of early-stage tumors, Jingwei Shida has remained committed to its vision and missi...
浏览次数:0
发布时间: 2025 - 11 - 19
On November 18, the 20th China Economic Forum, hosted by China Economic Weekly magazine under People's Daily, was successfully held at the Guangzhou Nansha International Convention Center.The China Economic Forum is a major economic forum event hosted by China Economic Weekly magazine under People's Daily. Since its inception in 2001, it has had a broad influence across government, business, and academic circles.It is reported that the theme of this year's forum is "Chinese Modernization and the Outlook for China's Economy in the 15th Five-Year Plan.&qu...
浏览次数:0
发布时间: 2025 - 11 - 12
Recently, Hangzhou Andao Pharmaceutical Co., Ltd. announced the completion of a Series C financing round exceeding RMB 400 million. This round was invested in by Grand Pharma (with Huadong Medicine as a major LP), Taiping Medical Health Fund, C&D Emerging Investment, Hangzhou Taikun, Zhejiang Province "4+1" Biopharmaceutical and High-End Medical Device Industry Fund, Guangzhou Industrial Investment, Guangzhou Development District, Science and Technology Financial Holding, and Hangzhou Talent Fund, among others, with follow-on investments from existing shareholders including Efung...
浏览次数:0
发布时间: 2025 - 11 - 03
Recently, Betta Pharmaceuticals and Shengsi Bio reached a comprehensive strategic cooperation agreement. Betta Pharmaceuticals will provide support to Shengsi Bio across R&D, clinical development, manufacturing, registration, and sales & marketing to facilitate the R&D, industrialization, and commercialization of related products. Additionally, the two companies signed a commercial cooperation agreement granting Betta Pharmaceuticals exclusive distribution rights for FRSW117 (a long-acting recombinant coagulation factor VIII-Fc fusion protein for injection) in the Greater China reg...
浏览次数:0
51页次9/13首页PREV...  45678910111213NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务